231 related articles for article (PubMed ID: 38778353)
41. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
42. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
43. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
[TBL] [Abstract][Full Text] [Related]
44. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
[TBL] [Abstract][Full Text] [Related]
45. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
[TBL] [Abstract][Full Text] [Related]
46. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
Schindler SE; Bollinger JG; Ovod V; Mawuenyega KG; Li Y; Gordon BA; Holtzman DM; Morris JC; Benzinger TLS; Xiong C; Fagan AM; Bateman RJ
Neurology; 2019 Oct; 93(17):e1647-e1659. PubMed ID: 31371569
[TBL] [Abstract][Full Text] [Related]
47. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M;
Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729
[TBL] [Abstract][Full Text] [Related]
48. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
49. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
50. A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease.
Gonzalez-Ortiz F; Ferreira PCL; González-Escalante A; Montoliu-Gaya L; Ortiz-Romero P; Kac PR; Turton M; Kvartsberg H; Ashton NJ; Zetterberg H; Harrison P; Bellaver B; Povala G; Villemagne VL; Pascoal TA; Ganguli M; Cohen AD; Minguillon C; Contador J; Suárez-Calvet M; Karikari TK; Blennow K
Alzheimers Dement; 2024 Feb; 20(2):1239-1249. PubMed ID: 37975513
[TBL] [Abstract][Full Text] [Related]
51. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.
Albani D; Marizzoni M; Ferrari C; Fusco F; Boeri L; Raimondi I; Jovicich J; Babiloni C; Soricelli A; Lizio R; Galluzzi S; Cavaliere L; Didic M; Schönknecht P; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Bocchio L; Salvatore M; Rossini PM; Tsolaki M; Visser PJ; Richardson JC; Wiltfang J; Bordet R; Blin O; Forloni G; Frisoni GB;
J Alzheimers Dis; 2019; 69(1):37-48. PubMed ID: 30149449
[TBL] [Abstract][Full Text] [Related]
52. Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF; Ashton NJ; Karikari TK; Strikwerda-Brown C; Köbe T; Gonneaud J; Pichet Binette A; Ozlen H; Yakoub Y; Simrén J; Pannee J; Lantero-Rodriguez J; Labonté A; Baker SL; Schöll M; Vanmechelen E; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Ann Neurol; 2022 Apr; 91(4):548-560. PubMed ID: 35084051
[TBL] [Abstract][Full Text] [Related]
53. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
54. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
55. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.
Sheng C; Yang K; He B; Du W; Cai Y; Han Y
Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860
[TBL] [Abstract][Full Text] [Related]
56. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
57. Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
Tideman P; Stomrud E; Leuzy A; Mattsson-Carlgren N; Palmqvist S; Hansson O;
Neurology; 2022 Apr; 98(15):e1525-e1533. PubMed ID: 35022305
[TBL] [Abstract][Full Text] [Related]
58. Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease.
Chong JR; Ashton NJ; Karikari TK; Tanaka T; Saridin FN; Reilhac A; Robins EG; Nai YH; Vrooman H; Hilal S; Zetterberg H; Blennow K; Lai MKP; Chen CP
Alzheimers Dement; 2021 Oct; 17(10):1649-1662. PubMed ID: 33792168
[TBL] [Abstract][Full Text] [Related]
59. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
[TBL] [Abstract][Full Text] [Related]
60. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases.
Brum WS; Cullen NC; Janelidze S; Ashton NJ; Zimmer ER; Therriault J; Benedet AL; Rahmouni N; Tissot C; Stevenson J; Servaes S; Triana-Baltzer G; Kolb HC; Palmqvist S; Stomrud E; Rosa-Neto P; Blennow K; Hansson O
Nat Aging; 2023 Sep; 3(9):1079-1090. PubMed ID: 37653254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
